CD28 and neoplasm: Based on results obtained with CAR-T (CD3z-CD28) cells, the regimen used for CAR-T (3Z-41BB) cells was modified: dosing at 0.02 million cells per egg, i.e., an effector-to-tumor ratio (E:T) of 0.2:1, either once at EDD11, or twice at EDD11 and EDD14.